<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05117138</url>
  </required_header>
  <id_info>
    <org_study_id>MHSW016</org_study_id>
    <nct_id>NCT05117138</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors</brief_title>
  <official_title>Safety and Efficacy of Chimeric Antigen Receptor T Lymphocytes for Patients With Intermediate and Advanced Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single arm, open-label, single center, cohort study to determine the efficacy and&#xD;
      safety of AMT-116 CAR-T cells in patients with moderate or far advanced non-small cell lung&#xD;
      carcinoma (NSCLC) and squamous cell cancer of the head and neck (HNSCC)，AMT-253 CAR-T cells&#xD;
      in patients with moderate or far advanced melanoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>One year recurrence rate</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival(PFS)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse Free Survival(RFS)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Melanoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>NSCLC/HNSCC：AMT-116 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate or far advanced non-small cell lung carcinomav or head and neck Squamous Cell Carcinoma.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MEL：AMT-253 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with moderate or far advanced melanoma.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMT-116 CAR-T cells</intervention_name>
    <description>Classical &quot;3+3&quot; dose escalation will be applied to 9 subjects with moderate or far advanced non-small cell lung carcinoma (NSCLC) enrolled.&#xD;
Classical &quot;3+3&quot; dose escalation will be applied to 9 subjects with moderate or far advanced head and neck Squamous Cell Carcinoma (HNSCC) enrolled.</description>
    <arm_group_label>NSCLC/HNSCC：AMT-116 CAR-T cells</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AMT-253 CAR-T cells</intervention_name>
    <description>1.The classic &quot;3 + 3&quot; dose escalation will be applied to 9 selected subjects with moderate or far advanced melanoma by intravenous drip.&#xD;
2.3 ~ 6 patients with intermediate and advanced melanoma will be injected intratumorally at a dose of ≤ 1 × 10^8 cells.&#xD;
3.3 ~ 6 patients with operable advanced melanoma will be treated with postoperative adjuvant treatment at a dose of ≤ 1 × 10^8 cells ≤ intravenous drip on Day 1 of each 42 days cycle (8 cycle maximum).</description>
    <arm_group_label>MEL：AMT-253 CAR-T cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-70 years old, both men and women, and the survival period is more than 6&#xD;
             months.&#xD;
&#xD;
          -  At least one assessable focus, failure of previous multi-line treatment or stable&#xD;
             condition after treatment.&#xD;
&#xD;
          -  Patients with melanoma confirmed by histopathology, patients with non-small cell lung&#xD;
             cancer(squamous carcinoma) and head and neck squamous cell carcinoma.&#xD;
&#xD;
          -  The surgically removed pathological tissue can be used for immunohistochemical&#xD;
             detection of target protein (paraffin section should be within 5 years), and the&#xD;
             positive expression of target protein in line with pathological diagnosis&#xD;
             (immunohistochemical staining + + or + + +).&#xD;
&#xD;
          -  Sufficient venous access for blood sampling and venous blood sampling, no&#xD;
             contraindications for lymphocyte collection.&#xD;
&#xD;
          -  Routine blood examination: white blood cell count (WBC) ≥ 3 × 10^9 / L, lymphocyte&#xD;
             count (ly) ≥ 0.8 × 10^9 / L, hemoglobin (HB) ≥ 90g / L, platelet (PLT) ≥ 80 × 10^9/L.&#xD;
&#xD;
          -  Liver and kidney function: alanine aminotransferase and aspartate aminotransferase &lt; 3&#xD;
             ULN, total bilirubin (TBIL) &lt; 1.5 ULN, serum creatinine (SCR) &lt; 2 ULN.&#xD;
&#xD;
          -  The subjects voluntarily joined the study, signed the informed consent form, had good&#xD;
             compliance and cooperated with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active hepatitis B or hepatitis C virus, HIV infection, or other unhealed active&#xD;
             infections.&#xD;
&#xD;
          -  Patients with second tumor.&#xD;
&#xD;
          -  Patients previously treated with car-t cells.&#xD;
&#xD;
          -  Requiring long-term use of immunosuppressants for any reason.&#xD;
&#xD;
          -  Any serious and uncontrolled systemic autoimmune disease or any unstable systemic&#xD;
             disease, including but not limited to systemic lupus erythematosus, rheumatoid&#xD;
             arthritis, ulcerative colitis, Crohn's disease and temporal arteritis.&#xD;
&#xD;
          -  Subjects with severe heart, lung, liver and kidney dysfunction or severe lung&#xD;
             diseases.&#xD;
&#xD;
          -  Current systemic use of steroid cells (except for recent or current use of inhaled&#xD;
             steroids).&#xD;
&#xD;
          -  Pregnant and lactating subjects.&#xD;
&#xD;
          -  Allergic to immunotherapy and related cells.&#xD;
&#xD;
          -  Subjects with a history of organ transplantation or waiting for organ transplantation.&#xD;
&#xD;
          -  After evaluation, the investigator considered that the subjects were unable or&#xD;
             unwilling to comply with the requirements of the study protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Zhang, M.D.</last_name>
      <email>yizhang@zzu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Yi Zhang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 11, 2021</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

